🔎 Trials Near Me

Akèy › Maladi Alzheimer › Florid › Orlando

Etid klinik pou Maladi Alzheimer nan Orlando, FL

25 etid pou Maladi Alzheimer ap chèche patisipan nan sit nan ak bò kote Orlando (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis

Ap rekriteFaz 2
  • Clinical Site, Orlando
Laj 55 a 90 · Tout sèks · Mizajou Sep 30, 2026 · NCT06887192

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

Ap rekriteFaz 2
  • K2 Medical Research, Maitland · 6 mi lwen
Laj 55 ak plis · Tout sèks · Mizajou Sep 29, 2026 · NCT06540833

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

Ap rekriteFaz 3
  • Local Institution - 1635, Orlando
Laj 55 a 90 · Tout sèks · Mizajou Sep 28, 2026 · NCT06937229

A Study of LY3439539 in Participants With Alzheimer's Disease

Ap rekriteFaz 1
  • Charter Research, Orlando
  • AdventHealth Orlando, Orlando
  • K2 Medical Research, Maitland · 6 mi lwen
Laj 50 a 85 · Tout sèks · Mizajou Sep 24, 2026 · NCT07598370

A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

Ap rekriteFaz 3
  • Charter Research Orlando, Orlando
  • Nova Psychiatry, Orlando
  • Combined Research Orlando Phase I-IV LLC, Orlando
  • ak 1 plis
Laj 55 a 90 · Tout sèks · Mizajou Sep 22, 2026 · NCT06585787

A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)

Ap rekriteFaz 2
  • Charter Research - Orlando, Orlando
  • Conquest Research, Winter Park · 5 mi lwen
  • K2 Medical Research ORLANDO, Maitland · 6 mi lwen
Laj 55 a 85 · Tout sèks · Mizajou Sep 22, 2026 · NCT07589595

Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

Ap rekriteFaz 2
  • Conquest Research - Lake Nona, Orlando
Laj 55 a 80 · Tout sèks · Mizajou Sep 21, 2026 · NCT06847321

Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

Ap rekriteFaz 3
  • Charter Research - Winter Park/Orlando, Orlando
  • Conquest Research - Lake Nona, Orlando
  • Conquest Research, LLC, Winter Park · 5 mi lwen
  • ak 2 plis
Laj 50 a 90 · Tout sèks · Mizajou Sep 21, 2026 · NCT07177352

A Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease

Ap rekriteFaz 1/2
  • Conquest Research - Winter Park /ID# 277760, Winter Park · 5 mi lwen
  • K2 Medical Research - Clermont /ID# 277859, Clermont · 24 mi lwen
Laj 50 a 90 · Tout sèks · Mizajou Sep 18, 2026 · NCT07599670

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

Ap rekriteFaz 3
  • Combined Research Orlando (CRO), Orlando
  • Local Institution - 1622, Maitland · 6 mi lwen
  • Local Institution - 1631, Maitland · 6 mi lwen
Laj 55 a 90 · Tout sèks · Mizajou Sep 16, 2026 · NCT07011732

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

Ap rekriteFaz 3
  • Local Institution - 2634, Orlando
Laj 55 a 90 · Tout sèks · Mizajou Sep 16, 2026 · NCT07011745

A Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease

Ap rekriteFaz 3
  • K2 Medical Research, LLC, Maitland · 6 mi lwen
Laj 55 a 80 · Tout sèks · Mizajou Sep 10, 2026 · NCT07717411

Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

Ap rekriteFaz 2
  • ClinCloud, Maitland · 6 mi lwen
  • Local Institution - 0007, Maitland · 6 mi lwen
Laj 55 a 90 · Tout sèks · Mizajou Sep 1, 2026 · NCT06808984

A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)

Ap rekriteFaz 2
  • Charter Research - Orlando ( Site 1051), Orlando
  • Conquest Research LLC ( Site 1053), Winter Park · 5 mi lwen
  • K2 Medical Research ( Site 1047), Maitland · 6 mi lwen
Laj 50 a 85 · Tout sèks · Mizajou Aug 26, 2026 · NCT07033494

A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

Ap rekriteFaz 1
  • K2 Medical Research, LLC, Maitland · 6 mi lwen
Laj 50 a 85 · Tout sèks · Mizajou Aug 24, 2026 · NCT06297590

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

Ap rekriteFaz 1/2
  • Charter Research, LLC, Orlando
  • Headlands Horizons LLC, Orlando
Laj 35 a 85 · Tout sèks · Mizajou Jul 10, 2026 · NCT05462106

Low-Dose Radiotherapy for Alzheimer's Disease

Ap rekriteFaz 1/2
  • Renaissance Institute of Precision Oncology & Radiosurgery, Winter Park · 5 mi lwen
Laj 50 ak plis · Tout sèks · Mizajou Jul 9, 2026 · NCT07693140

A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).

Ap rekriteFaz 3
  • Charter Research - Orlando, Orlando
  • Headlands Research Orlando, Orlando
  • Conquest Research, Winter Park · 5 mi lwen
  • ak 1 plis
Laj 55 ak plis · Tout sèks · Mizajou Jul 7, 2026 · NCT07602582

A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease

Ap rekriteFaz 2
  • Conquest Research, Winter Park · 5 mi lwen
  • K2 Medical Research LLC, Maitland · 6 mi lwen
  • K2 Medical Research LLC, Maitland · 6 mi lwen
Laj 50 a 85 · Tout sèks · Mizajou Jun 26, 2026 · NCT07094516

A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)

Ap rekriteFaz 1Volontè an sante akeyi
  • K2 Medical Research, Maitland · 6 mi lwen
Laj 45 a 85 · Tout sèks · Mizajou Jun 4, 2026 · NCT06657768

[18F]PI-2620 Phase 3 Histopathological Study

Ap rekriteFaz 3
  • Charter Research, Winter Park · 5 mi lwen
  • K2 Medical Research, Maitland · 6 mi lwen
Laj 50 ak plis · Tout sèks · Mizajou May 22, 2026 · NCT05641688

Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia

Ap rekriteEtid obsèvasyonVolontè an sante akeyi
  • Charter Research, Orlando
  • Conquest Research, Winter Park · 5 mi lwen
  • K2 Medical Research, Maitland · 6 mi lwen
  • ak 1 plis
Laj 60 a 90 · Tout sèks · Mizajou Apr 15, 2026 · NCT06584357

Open-label Extension Study in Participants With Early Alzheimer's Disease

Ap rekriteFaz 2
  • GSK Investigational Site, Maitland · 6 mi lwen
Laj 50 a 85 · Tout sèks · Mizajou Feb 2, 2026 · NCT07105709

ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease

Ap rekrite
  • Advent Health, Orlando
Laj 50 a 85 · Tout sèks · Mizajou Jan 9, 2026 · NCT03671889

University of Central Florida CereBank

Ap rekriteEtid obsèvasyonVolontè an sante akeyi
  • University of Central Florida, Orlando
Laj 18 ak plis · Fanm · Mizajou Mar 14, 2025 · NCT06876857

Etid Maladi Alzheimer nan lòt vil

Lòt etid nan Orlando

Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.